Evommune Inc (EVMN)

$10.54 -0.02 (-0.19%)
Market Cap 382.52M
Revenue (ttm) 13.00M
Net Income (ttm) -68.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -529.77%
Debt to Equity Ratio 0.00
Volume 388,900
Avg Vol 664,208
Day's Range N/A - N/A
Shares Out 36.29M
Stochastic %K 8%
Beta N/A
Analysts Strong Sell
Price Target $24.55

Company Profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Industry: Biotechnology
Sector: Healthcare
Phone: (925) 247-4481
Address:
1891 Page Mill Road, Palo Alto, United States
prismmarketview
prismmarketview Sep. 9 at 4:11 PM
PRISM Mid-Day Movers: Pharmaceuticals and Biotech are Today's Leaders. Opus Genetics, Inc. (NASDAQ: $IRD ) surged, up 26.5% to $5.49 today, rebounding sharply from yesterday’s $4.34 close. Pulse Biosciences, Inc. (NASDAQ: $PLSE ) climbed 18.24% to $57.69 today, gaining $8.90 from its previous $48.79 close. Other Notable Movers: bioAffinity Tech ($BIAF ) up 14% Skye Bioscience ($SKYE ) up 10% Evommune, Inc. ($EVMN ) down -16% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-biotech-are-todays-leaders/
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 9 at 12:17 PM
$EVMN (-10.1% pre) Evommune Halts Atopic Dermatitis Program Following Trial Failure https://ooc.bz/l/113610
0 · Reply
Mden
Mden Sep. 9 at 12:07 PM
$EVMN still holding up extremely well.
1 · Reply
topstockalerts
topstockalerts Sep. 9 at 2:25 AM
Evommune released preliminary Phase 2b results for EVO756 in moderate-to-severe atopic dermatitis, a key clinical milestone that the company had identified for September 2026. The results appear to have disappointed investors, sending the stock sharply lower after the drug had already come under pressure following an earlier trial failure in chronic spontaneous urticaria. In June, EVO756 failed to meet the primary endpoint in its Phase 2b urticaria trial at any tested dose, leading Evommune to discontinue development in that indication. The setback prompted William Blair to downgrade the stock to Market Perform and weakened investor confidence ahead of the atopic dermatitis data. $EVMN
0 · Reply
DonCorleone77
DonCorleone77 Sep. 9 at 12:57 AM
$CASY $BNED $EVMN $TH $INGM AFTER-HOURS MOVERS: Currently Higher After Earnings: - InnovAge Holding (INNV) up 9.5% Currently Also Higher: - Chime Financial (CHYM) up 9.0% after acquisition of Stride Bank and raised guidance Currently Lower After Earnings: - ServiceTitan (TTAN) down 20.3% - MIND Technology (MIND) down 13.3% - Braze (BRZE) down 12.3% - Casey's General Stores (CASY) down 8.3% - Barnes & Noble Education (BNED) down 1.9% Currently Also Lower: - Evommune (EVMN) down 15.8% after EV0756 trial did not meet primary and secondary endpoints - Target Hospitality (TH) down 6.9% after equity offering - Ingram Micro (INGM) down 6.3% after equity offering.
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 8 at 11:51 PM
Why Is EVMN Stock Down 13% After-Hours? $EVMN $VTI $IWM https://stocktwits.com/news/equity/markets/why-is-evmn-stock-down-13-after-hours/cZtEX8dRJy7
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Sep. 8 at 11:42 PM
$EVMN for now….
0 · Reply
Mden
Mden Sep. 8 at 11:13 PM
$EVMN less than15% price drop, not too bad after drug failure
1 · Reply
notreload_ai
notreload_ai Sep. 8 at 10:06 PM
$EVMN shares fell after hours as EVO756 missed its Phase 2b atopic dermatitis goal. The company will not advance the drug in eczema and shifts focus to EVO301. https://notreload.xyz/xy/evommune-shares-slide-after-second-mid-stage-miss-for-oral-eczema-drug/
0 · Reply
theSnip3r
theSnip3r Sep. 8 at 9:50 PM
$EVMN was the news bad ????
1 · Reply
Latest News on EVMN
Evommune price target lowered to $23 from $28 at Clear Street

2026-09-09T23:50:16.000Z - 4 days ago

Evommune price target lowered to $23 from $28 at Clear Street

Evommune price target lowered to $18 from $32 at Raymond James

2026-09-09T12:55:48.000Z - 4 days ago

Evommune price target lowered to $18 from $32 at Raymond James

Evommune price target lowered to $22 from $28 at Leerink

2026-09-09T12:40:16.000Z - 4 days ago

Evommune price target lowered to $22 from $28 at Leerink

Evommune price target lowered to $21 from $29 at RBC Capital

2026-09-09T12:38:53.000Z - 4 days ago

Evommune price target lowered to $21 from $29 at RBC Capital

Evommune scraps eczema drug after trial miss, shares plunge

Sep 8, 2026, 6:18 PM EDT - 5 days ago

Evommune scraps eczema drug after trial miss, shares plunge

Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints

2026-09-08T21:50:12.000Z - 5 days ago

Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints

Evommune down 31% at $9 after Phase 2b EVO-756 study results

2026-09-08T21:50:07.000Z - 5 days ago

Evommune down 31% at $9 after Phase 2b EVO-756 study results

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Sep 8, 2026, 5:43 PM EDT - 5 days ago

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Evommune initiated with a Buy at Needham

2026-08-26T10:40:24.000Z - 18 days ago

Evommune initiated with a Buy at Needham

Evommune price target lowered to $29 from $30 at RBC Capital

2026-08-07T12:21:01.000Z - 5 weeks ago

Evommune price target lowered to $29 from $30 at RBC Capital

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Aug 6, 2026, 4:05 PM EDT - 5 weeks ago

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Evommune Slides: Corporate presentation

Aug 6, 2026, 4:00 PM EDT - 5 weeks ago

Evommune Slides: Corporate presentation

Evommune Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

Evommune Quarterly report: Q2 2026

Evommune Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

Evommune Earnings release: Q2 2026

Evommune initiates Phase 2b trial of EVO756

2026-07-30T12:22:34.000Z - 6 weeks ago

Evommune initiates Phase 2b trial of EVO756

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Jul 30, 2026, 8:00 AM EDT - 6 weeks ago

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Evommune participates in a conference call with Cantor

2026-07-29T20:28:13.000Z - 6 weeks ago

Evommune participates in a conference call with Cantor

Clear Street sees attractive point into Evommune after selloff

2026-07-16T14:00:18.000Z - 1 month ago

Clear Street sees attractive point into Evommune after selloff

Septerna price target lowered to $45 from $52 at Guggenheim

2026-07-01T10:50:37.000Z - 2 months ago

Septerna price target lowered to $45 from $52 at Guggenheim

SEPN

Evommune price target lowered to $26 from $55 at Morgan Stanley

2026-06-30T11:00:29.000Z - 2 months ago

Evommune price target lowered to $26 from $55 at Morgan Stanley

Evommune downgraded to Neutral from Buy at H.C. Wainwright

2026-06-30T10:05:57.000Z - 2 months ago

Evommune downgraded to Neutral from Buy at H.C. Wainwright

Evommune price target lowered to $28 from $53 at Clear Street

2026-06-29T20:20:55.000Z - 2 months ago

Evommune price target lowered to $28 from $53 at Clear Street

Evommune downgraded to Market Perform from Outperform at William Blair

2026-06-29T13:40:41.000Z - 2 months ago

Evommune downgraded to Market Perform from Outperform at William Blair

Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint

2026-06-29T12:35:45.000Z - 2 months ago

Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Jun 29, 2026, 8:30 AM EDT - 2 months ago

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Evommune Transcript: AGM 2026

Jun 2, 2026, 11:30 AM EDT - 3 months ago

Evommune Transcript: AGM 2026

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 7, 2026, 4:05 PM EDT - 4 months ago

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Evommune Quarterly report: Q1 2026

Evommune Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Evommune Earnings release: Q1 2026

Evommune Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 4 months ago

Evommune Slides: Corporate presentation

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Evommune Proxy statement: Proxy filing

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Evommune Proxy statement: Proxy filing

Evommune Registration statement: Registration filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Evommune Registration statement: Registration filing

Evommune Transcript: Status update

Apr 13, 2026, 2:00 PM EDT - 5 months ago

Evommune Transcript: Status update

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Apr 6, 2026, 9:00 AM EDT - 5 months ago

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Mar 5, 2026, 4:01 PM EST - 6 months ago

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 6 months ago

Evommune Earnings release: Q4 2025

Evommune Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 6 months ago

Evommune Annual report: Q4 2025

Evommune Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 6 months ago

Evommune Slides: Corporate presentation

Evommune Announces $125 Million Private Placement

Feb 12, 2026, 8:30 PM EST - 7 months ago

Evommune Announces $125 Million Private Placement

Evommune Transcript: Study result

Feb 10, 2026, 8:30 AM EST - 7 months ago

Evommune Transcript: Study result

Evommune Press release: Study result

Feb 10, 2026, 8:30 AM EST - 7 months ago

Evommune Press release: Study result

Evommune Slides: Study result

Feb 10, 2026, 8:30 AM EST - 7 months ago

Evommune Slides: Study result

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Feb 10, 2026, 7:30 AM EST - 7 months ago

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Evommune Slides: Corporate presentation

Jan 7, 2026, 7:00 AM EST - 8 months ago

Evommune Slides: Corporate presentation

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Dec 11, 2025, 4:05 PM EST - 9 months ago

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Evommune Quarterly report: Q3 2025

Dec 11, 2025, 4:00 PM EST - 9 months ago

Evommune Quarterly report: Q3 2025

Evommune Earnings release: Q3 2025

Dec 11, 2025, 4:00 PM EST - 9 months ago

Evommune Earnings release: Q3 2025

Evommune Slides: Corporate Presentation

Dec 11, 2025, 4:00 PM EST - 9 months ago

Evommune Slides: Corporate Presentation

Evommune Announces Pricing of its Initial Public Offering

Nov 5, 2025, 7:45 PM EST - 10 months ago

Evommune Announces Pricing of its Initial Public Offering

Evommune Announces Commencement of Initial Public Offering

Oct 30, 2025, 6:30 AM EDT - 10 months ago

Evommune Announces Commencement of Initial Public Offering

Evommune Registration statement: Registration Filing

Oct 17, 2025, 8:00 AM EDT - 11 months ago

Evommune Registration statement: Registration Filing

Evommune files for IPO to advance immune drug work

Oct 10, 2025, 8:31 AM EDT - 11 months ago

Evommune files for IPO to advance immune drug work

Evommune IPO Registration Document (S-1)

Oct 9, 2025, 2:18 PM EDT - 11 months ago

Evommune IPO Registration Document (S-1)

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

Oct 9, 2025, 10:32 AM EDT - 11 months ago

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

prismmarketview
prismmarketview Sep. 9 at 4:11 PM
PRISM Mid-Day Movers: Pharmaceuticals and Biotech are Today's Leaders. Opus Genetics, Inc. (NASDAQ: $IRD ) surged, up 26.5% to $5.49 today, rebounding sharply from yesterday’s $4.34 close. Pulse Biosciences, Inc. (NASDAQ: $PLSE ) climbed 18.24% to $57.69 today, gaining $8.90 from its previous $48.79 close. Other Notable Movers: bioAffinity Tech ($BIAF ) up 14% Skye Bioscience ($SKYE ) up 10% Evommune, Inc. ($EVMN ) down -16% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-biotech-are-todays-leaders/
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 9 at 12:17 PM
$EVMN (-10.1% pre) Evommune Halts Atopic Dermatitis Program Following Trial Failure https://ooc.bz/l/113610
0 · Reply
Mden
Mden Sep. 9 at 12:07 PM
$EVMN still holding up extremely well.
1 · Reply
topstockalerts
topstockalerts Sep. 9 at 2:25 AM
Evommune released preliminary Phase 2b results for EVO756 in moderate-to-severe atopic dermatitis, a key clinical milestone that the company had identified for September 2026. The results appear to have disappointed investors, sending the stock sharply lower after the drug had already come under pressure following an earlier trial failure in chronic spontaneous urticaria. In June, EVO756 failed to meet the primary endpoint in its Phase 2b urticaria trial at any tested dose, leading Evommune to discontinue development in that indication. The setback prompted William Blair to downgrade the stock to Market Perform and weakened investor confidence ahead of the atopic dermatitis data. $EVMN
0 · Reply
DonCorleone77
DonCorleone77 Sep. 9 at 12:57 AM
$CASY $BNED $EVMN $TH $INGM AFTER-HOURS MOVERS: Currently Higher After Earnings: - InnovAge Holding (INNV) up 9.5% Currently Also Higher: - Chime Financial (CHYM) up 9.0% after acquisition of Stride Bank and raised guidance Currently Lower After Earnings: - ServiceTitan (TTAN) down 20.3% - MIND Technology (MIND) down 13.3% - Braze (BRZE) down 12.3% - Casey's General Stores (CASY) down 8.3% - Barnes & Noble Education (BNED) down 1.9% Currently Also Lower: - Evommune (EVMN) down 15.8% after EV0756 trial did not meet primary and secondary endpoints - Target Hospitality (TH) down 6.9% after equity offering - Ingram Micro (INGM) down 6.3% after equity offering.
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 8 at 11:51 PM
Why Is EVMN Stock Down 13% After-Hours? $EVMN $VTI $IWM https://stocktwits.com/news/equity/markets/why-is-evmn-stock-down-13-after-hours/cZtEX8dRJy7
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Sep. 8 at 11:42 PM
$EVMN for now….
0 · Reply
Mden
Mden Sep. 8 at 11:13 PM
$EVMN less than15% price drop, not too bad after drug failure
1 · Reply
notreload_ai
notreload_ai Sep. 8 at 10:06 PM
$EVMN shares fell after hours as EVO756 missed its Phase 2b atopic dermatitis goal. The company will not advance the drug in eczema and shifts focus to EVO301. https://notreload.xyz/xy/evommune-shares-slide-after-second-mid-stage-miss-for-oral-eczema-drug/
0 · Reply
theSnip3r
theSnip3r Sep. 8 at 9:50 PM
$EVMN was the news bad ????
1 · Reply
negligiblecat
negligiblecat Sep. 8 at 9:48 PM
$EVMN ouch feel bad for the bulls
0 · Reply
EliteXTradeRoom
EliteXTradeRoom Sep. 8 at 7:05 PM
$EVMN In at $13 target 1 $14+
0 · Reply
Tradr1205
Tradr1205 Aug. 31 at 3:53 PM
$EVMN I back in! I think she's trading back above $14 very soon!
0 · Reply
JRshocker
JRshocker Jul. 30 at 3:18 PM
$EVMN is anyone here?
3 · Reply
SevenPhigs27
SevenPhigs27 Jul. 22 at 7:23 PM
$EVMN Took a starter. GLTA
0 · Reply
elmono
elmono Jul. 14 at 11:12 PM
$EVMN ageing nicely. Shkreli nice contrarian indicator
0 · Reply
fda_tracker
fda_tracker Jul. 14 at 2:54 PM
$EVMN Phase 2 trial w/est Jul completion date NCT07150845: https://www.clinicaltrials.gov/study/NCT07150845 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
FilingTracker
FilingTracker Jul. 9 at 12:01 AM
$EVMN Insider bought the dip: https://filingtracker.ai/filing/2044725/0001290976-26-000004
0 · Reply
Market_Pulse_Report
Market_Pulse_Report Jul. 6 at 12:34 AM
$EVMN
0 · Reply
Market_Pulse_Report
Market_Pulse_Report Jul. 4 at 6:09 PM
$EVMN Check out this great informative video on this company tons of info https://youtu.be/PRNOWUopqig?si=IHiaYq4otfM9aRJT
0 · Reply
Robby83
Robby83 Jul. 2 at 4:24 PM
$EVMN well back down to my entry... lots of selling pressure breaking my chart setup
0 · Reply
Timefortendies77
Timefortendies77 Jul. 1 at 9:00 PM
$CLDX got a bit of extra hype on the Russel 2000 and then the $EVMN crash. We are undisputed #1 for mast cell diseases right now and first to market if all goes well.
0 · Reply